MBX Biosciences, Inc. (MBX)
54.11
-0.05
(-0.09%)
USD |
NASDAQ |
Oct 29, 16:00
54.11
0.00 (0.00%)
After-Hours: 19:58
MBX Biosciences Enterprise Value : 2.182B for Oct. 28, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 28, 2026 | 2.182B |
| October 27, 2026 | 2.125B |
| October 26, 2026 | 1.996B |
| October 23, 2026 | 1.910B |
| October 22, 2026 | 2.004B |
| October 21, 2026 | 2.171B |
| October 20, 2026 | 2.150B |
| October 19, 2026 | 2.101B |
| October 16, 2026 | 1.964B |
| October 15, 2026 | 2.016B |
| October 14, 2026 | 1.926B |
| October 13, 2026 | 1.934B |
| October 12, 2026 | 2.079B |
| October 09, 2026 | 2.138B |
| October 08, 2026 | 2.138B |
| October 07, 2026 | 2.200B |
| October 06, 2026 | 2.314B |
| October 05, 2026 | 2.392B |
| October 02, 2026 | 2.390B |
| October 01, 2026 | 2.296B |
| September 30, 2026 | 2.396B |
| September 29, 2026 | 2.354B |
| September 28, 2026 | 2.344B |
| September 25, 2026 | 2.156B |
| September 24, 2026 | 2.241B |
| Date | Value |
|---|---|
| September 23, 2026 | 2.361B |
| September 22, 2026 | 2.557B |
| September 21, 2026 | 2.507B |
| September 18, 2026 | 2.601B |
| September 17, 2026 | 2.648B |
| September 16, 2026 | 2.537B |
| September 15, 2026 | 2.514B |
| September 14, 2026 | 2.437B |
| September 11, 2026 | 2.415B |
| September 10, 2026 | 2.507B |
| September 09, 2026 | 2.601B |
| September 08, 2026 | 2.605B |
| September 04, 2026 | 2.544B |
| September 03, 2026 | 2.530B |
| September 02, 2026 | 2.504B |
| September 01, 2026 | 2.506B |
| August 31, 2026 | 2.538B |
| August 28, 2026 | 2.606B |
| August 27, 2026 | 2.768B |
| August 26, 2026 | 2.786B |
| August 25, 2026 | 2.875B |
| August 24, 2026 | 2.768B |
| August 21, 2026 | 2.765B |
| August 20, 2026 | 2.766B |
| August 19, 2026 | 2.865B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.882B |
| Corcept Therapeutics, Inc. | 9.013B |
| Veru, Inc. | 15.60M |
| Johnson & Johnson | 679.85B |
| Eli Lilly & Co. | 1.259T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -37.10M |
| Total Expenses (Quarterly) | 37.10M |
| EPS Diluted (Quarterly) | -0.7777 |
| Earnings Yield | -4.45% |
| Normalized Earnings Yield | -4.447 |